Core Viewpoint - The company, Ginkgo Bioworks, is balancing operational sustainability with future growth through a dual strategy of "licensing in + independent research and development" to drive innovation and revenue generation [1][2]. Group 1: Business Strategy - Ginkgo Bioworks has achieved stable cash flow through the introduction of large commercial products while focusing on cutting-edge mRNA therapies, resulting in the development of key products such as EVM14, EVM16, and CAR-T [1][3]. - The company has established a comprehensive technology platform that includes antigen design, mRNA sequence optimization, lipid nanoparticle delivery technology, and industrial production capabilities, making it one of the few companies with end-to-end capabilities in the industry [3][6]. Group 2: Financial Performance - Financial data indicates that Ginkgo Bioworks expects to generate revenue of 707 million yuan in 2024, representing a year-on-year increase of 461%, driven by three commercialized products [3]. - The company aims to achieve sales of 10 billion yuan by 2030, leveraging its existing product portfolio [3]. Group 3: Competitive Advantage - Ginkgo Bioworks possesses a proprietary lipid library of over 500 types, which supports various projects including vaccines and CAR-T therapies [5][6]. - The company has developed an AI algorithm for efficient antigen sequence design, with its algorithm system now in its third generation, and has established a lipid nanoparticle delivery technology platform with patent protections [6]. Group 4: Market Position - Major pharmaceutical companies like AbbVie, Eli Lilly, Johnson & Johnson, and AstraZeneca are investing in mRNA therapies and CAR-T technologies, indicating a competitive landscape [4]. - Ginkgo Bioworks is one of the few domestic companies capable of full-process localized production of mRNA therapy drugs, enhancing its market position [6].

Core Viewpoint - The research team at Xi'an University of Electronic Science and Technology has developed a novel non-ionic delivery system that addresses the "toxicity-efficiency" dilemma in mRNA therapy, enhancing safety and efficacy in gene therapy applications [1][2]. Group 1: Technology Overview - The new delivery system, termed TNP, utilizes thiourea groups to form strong hydrogen bond networks with mRNA, allowing for efficient loading without charge dependence, unlike traditional lipid nanoparticles (LNP) [2]. - TNP significantly extends the in vivo expression duration of mRNA to seven times that of LNP, improves targeting efficiency to the spleen, and achieves a near 100% cell survival rate, indicating high biocompatibility [2][3]. Group 2: Mechanism of Action - TNP employs a unique intracellular transport mechanism that avoids the Rab11-mediated recycling pathway, achieving a high intracellular retention rate of 89.7%, compared to only 27.5% for LNP [2]. - The interaction between thiourea groups and endosomal membrane lipids induces membrane permeabilization, allowing for the direct release of intact mRNA into the cytoplasm, thus circumventing lysosomal degradation [2]. Group 3: Implications for Gene Therapy - The innovative non-ionic delivery technology is expected to lower the costs of gene therapy, making treatments more accessible for patients with rare and chronic diseases [3]. - The research team has already developed multiple targeted delivery systems based on this technology, which are currently in animal testing phases for applications in tumor immunotherapy and gene editing for rare diseases [3].